General Archive

-
News releasesLifeArc announces strategic partnership with PrecisionLife as part of its Motor Neuron Disease Translational Challenge
LifeArc and PrecisionLife will work together to select and validate multiple novel targets and their accompanying patient stratification biomarkers.
-
News releasesLifeArc & Cystic Fibrosis Trust announce new £15m research funding to fast track treatment of lung infections
Focussing on innovative approaches to improve quality of life for people with cystic fibrosis (CF)
-
News releasesDr Jason Slingsby joins LifeArc as Chief Business Officer
Jason will be responsible for developing, leading, and implementing LifeArc’s business development and partnering strategies.
-
ArticlesInternational Women’s Day 2023
Tips on career advancement, from some of LifeArc’s incredible women
-
ArticlesRare Disease Day 2023 – Robbie’s story
Robbie has a rare genetic neurodegenerative disease known as AP-4 Hereditary Spastic Paraplegia (AP-4 HSP) subtype SPG47.
-
News releases£1 million awarded to develop cutting-edge therapies for motor neuron disease
London, 24 January 2023: Medical research charity LifeArc, the Motor Neurone Disease Association (MND Association) and the My Name’5 Doddie…
-
Articles2022 wrapped – our highlights from a pivotal year
We’ve seen some exciting scientific progress, forged new partnerships and launched some new landmark initiatives.
-
News releasesLifeArc Ventures invests in Surgery Hero, world’s first digital coaching clinic for patients
Seed funding will be used to scale the solution through the application of machine learning
-
News releasesNew £30 million translational partnership will accelerate development of new treatments for people with dementia
Funding will accelerate development of new diagnostic tests, treatments, and devices for people with dementia.
-
News releasesPromising new asthma medicine ready to enter early clinical trials
LifeArc scientists instrumental to the development of the world’s first anti-IL17BR antibody, now being trialled as a treatment for severe…
-
News releasesLifeArc co-founded company RQ Bio signs licensing agreement with AstraZeneca worth up to $157m plus royalties for monoclonal antibodies against SARS-CoV-2
LONDON, UK, 17 May 2022 — LifeArc today announced that RQ Biotechnology Ltd (RQ Bio), a company it co-founded, has…
-
News releasesNew study explores unique approach to treat a rare liver disease
A research study looking into a new approach to treat primary sclerosing cholangitis (PSC) is progressing to clinical trials.
